2024 targets achieved; markets appreciated shareholder rewards
30/01/25 -"Even though Q4 results were somewhat behind the consensus, Sanofi slightly exceeded its 2024 guidance. The 2025 outlook was encouraging. Moreover, the investors welcomed the management’s ..."
Pages
66
Language
English
Published on
30/01/25
You may also be interested by these reports :
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...